Researchers in epigenetics have long faced a major challenge: after identifying dozens of potential regulatory factors, traditional CUT&Tag workflows typically allow validation of only one target at a time. To determine whether these factors regulate the same set of genes, researchers may need to perform repeated experiments for each target, consuming months of time, significant funding, and valuable limited samples.
Today, this bottleneck has been overcome.
Hangzhou PTM BIO Technology Co., Ltd. (hereinafter referred to as “PTM BIO”) announced the launch of its proprietary next-generation multiplex epigenomic profiling technology — Hi-Plex CUT&Tag (HCT). Powered by patented antibody-conjugation technology and targeted transposase regulation systems, HCT enables, for the first time globally, simultaneous profiling of 3–30 distinct targets within the same DNA molecules from a single low-input sample through a single experimental workflow. This breakthrough advances epigenetic research beyond “single-target mapping” toward comprehensive “multiplex target profiling.”
HCT delivers far more than increased throughput — it represents a fundamental transformation in research workflows:
From individual target interrogation to regulatory network mapping:
For the first time, researchers can directly investigate, in their native genomic context, the coordinated or opposing relationships among histone modifications, transcription factors, and chromatin remodeling complexes.
From sample depletion to single-run profiling:
HCT addresses the critical challenge of limited sample availability in multiplex studies, including precious clinical specimens such as biopsy tissues and circulating tumor cells.
From batch variation to highly comparable datasets:
Because all targets are generated within the same reaction system, HCT minimizes batch effects and reduces false-positive signals caused by experimental variation.
This technological breakthrough enables researchers to systematically answer previously inaccessible biological questions:
Which targets are co-localized on the same genomic regions or regulatory elements?
Do different chromatin modifications exhibit synergistic or antagonistic relationships?
Following disease progression or therapeutic intervention, which combinations of regulatory factors truly drive biological changes?
For epigenetics researchers, HCT provides an unprecedented opportunity to generate comprehensive multiplex co-localization maps. For proteomics researchers, HCT completes a critical technological bridge between omics discovery and mechanistic validation. For translational and clinical researchers, HCT enables the characterization of disease-driving regulatory signatures directly from clinically relevant samples.
Advancing the Next Generation of Epigenomic Multi-Omics
As a leader in proteomics-driven precision medicine, PTM BIO’s HCT technology represents the culmination of more than a decade of expertise in protein modification antibodies and mass spectrometry-based proteomics. It marks a major transition in epigenetic research from single-target characterization to comprehensive multiplex regulatory analysis.
Building on HCT, PTM BIO has established an integrated technology ecosystem covering target panel design, library preparation workflows, and bioinformatics analysis, further strengthening its global competitiveness in the field of epigenomic multi-omics.
From pioneering protein modification omics, to becoming an industry leader in modification-specific antibodies, and now introducing the world’s first HCT technology, PTM BIO continues to drive scientific innovation through proprietary technologies. Moving forward, the company will continue supporting breakthroughs in basic biomedical research, cancer biology, developmental biology, and other areas of life science research.
About PTM BIO
Hangzhou PTM BIO Technology Co., Ltd. is an innovative high-tech company integrating research and development, manufacturing, and technology services. The company is committed to advancing the field of proteomics through continuous innovation and technological leadership.
With biological mass spectrometry as its core technology platform, combined with antibody reagent development, PTM BIO integrates expertise across biochemistry, pathology, cell biology, bioinformatics, and other interdisciplinary fields. The company has established an integrated business model combining high-throughput proteomic analysis with highly specific antibody development.
PTM BIO is among the pioneers providing comprehensive proteomics solutions spanning protein discovery, validation, and detection, supporting researchers across fundamental research, translational medicine, and clinical applications.
